Streetbeat News

Price Targets

TDUP

Morgan Stanley analyst Lauren Schenk has maintained an Equal-Weight rating on ThredUp (NASDAQ:TDUP) and lowered the price target from $4 to $3.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 2:05 pm

TASK

Morgan Stanley analyst James Faucette has maintained an Equal-Weight rating on TaskUs (NASDAQ:TASK) and lowered the price target from $13 to $12.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 2:04 pm

SIBN

Morgan Stanley analyst Drew Ranieri has maintained an Overweight rating on SI-BONE (NASDAQ:SIBN) but lowered the price target from $30 to $25.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 2:03 pm

SWAV

Morgan Stanley analyst Patrick Wood has maintained an Overweight rating on ShockWave Medical (NASDAQ:SWAV) but lowered the price target from $313 to $284.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 2:01 pm

H

Over the past 3 months, 6 analysts have published their opinion on Hyatt Hotels (NYSE:H) stock. The company has an average price target of $135.67 with a high of $147.00 and a low of $115.00. The average price target has increased by 0.57% over the past month.

Portfolio Pulse from Benzinga Insights

November 07, 2023 | 2:00 pm

RPD

Morgan Stanley analyst Erin Wilson has maintained an Equal-Weight rating on Rapid7 (NASDAQ:RPD) and raised the price target from $52 to $55.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 1:59 pm

QLYS

Morgan Stanley analyst Hamza Fodderwala maintains an Underweight rating on Qualys (NASDAQ:QLYS) and raises the price target from $104 to $137.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 1:58 pm

PEB

Morgan Stanley analyst Stephen Grambling has maintained an 'Underweight' rating on Pebblebrook Hotel (NYSE:PEB) and lowered the price target from $12 to $11.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 1:54 pm

PK

Morgan Stanley analyst Stephen Grambling maintains an Equal-Weight rating on Park Hotels & Resorts (NYSE:PK) and raises the price target from $12 to $13.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 1:53 pm

ENFN

UBS analyst Kevin Mcveigh has initiated coverage on Enfusion (NYSE:ENFN) with a Neutral rating and a price target of $9.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 1:52 pm